CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

CEA response may be a surrogate for response and long term outcome in (K)RAS wild-type mCRC receiving first-line targeted therapy. In the FIRE-3 trial, FOLFIRI and cetuximab induced a faster and greater CEA response than FOLFIRI and bevacizumab. CEA response correlated with longer PFS and OS. Hypothesizing that CEA reflects tumor burden greater CEA response may indicate greater antitumor efficacy.

from Cancer via ola Kala on Inoreader http://ift.tt/1Ryx8WG
via IFTTT